Meyka Pro banner
Erasca, Inc.

Erasca, Inc. (ERAS) Stock Overview

Explore Erasca, Inc.’s financial performance, market position, analyst ratings, and future outlook.

ERASNASDAQ
HealthcareBiotechnology
$18.61
$0.77(4.32%)
U.S. Market is Open · 15:09

Erasca, Inc. (ERAS)

Meyka AI Score

Z

Key Financials

Market Cap6.4B
P/E Ratio-20.10
EPS (TTM)$-0.93
ROE-0.77%
Fundamental Analysis

AI Price Forecasts

1 Month$18.89
3 Months$22.16
1 Year Target$19.54

ERAS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Erasca, Inc. (NASDAQ: ERAS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Erasca, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ERAS on the NASDAQ shows an RSI of 52.72, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $19.54 for the NASDAQ listing.

Key metrics behind Erasca, Inc.'s NASDAQ-traded stock include a P/E ratio of -20.10 and a market capitalization of 6.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ERAS on the NASDAQ.

Price Performance (NASDAQ: ERAS)

1-Day Change
3.03%
5-Day Change
1.04%
1-Month Change
-2.49%
3-Month Change
81.26%
6-Month Change
63.52%
Year-to-Date (YTD) Change
394.09%
1-Year Change
1212.86%
3-Year Change
604.21%
5-Year Change
-10.65%
All-Time (Max) Change
5.45%

Contact Information

858 465 6511
3115 Merryfield Row, San Diego, CA, 92121

Company Facts

1,030 Employees
IPO DateJul 16, 2021
CountryUS
Actively Trading

Frequently Asked Questions